^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Excerpt:
...BRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumor....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Excerpt:
...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Excerpt:
...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience

Excerpt:
Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation.
DOI:
10.1210/jc.2014-2246
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

Excerpt:
"The patient's PTC underwent a comprehensive genomic profile and was identified as harboring BRAF V600E. She started with 960 mg of vemurafenib twice daily...Two months later, repeat PET imaging demonstrated a dramatic reduction in both 18F-fluorodeoxyglucose avidity and mass size...
DOI:
10.1159/000363377
Evidence Level:
Sensitive: D – Preclinical
Title:

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

Published date:
01/09/2023
Excerpt:
Drug sensitivity assays of PTC organoid cultures demonstrated the intra- and inter-patient specific drug responses. BRAFV600E inhibitors, vemurafenib and dabrafenib monotherapy was mildly effective in treating BRAFV600E-mutant PTC organoids.
DOI:
10.1186/s12967-022-03848-z